Table 2.
Main Characteristics and Outcomes of Patients After SILS in Published Case Series
| Author, Year, Country | Publication Type | No. of Patients | Age of Patients (y) | BMI (kg/m2) | Diagnosis | Port System Applied in SILSa | Weight of Spleen (g) | Size of Incision in SILS (mm) | Duration of Procedure (min) | Blood Loss (mL) | Conversions (%) | Transfusion Needed | Hospital Stay (d) | Complications | Cosmesis |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Boone et al,7 2013, USA | Retrospective, comparative study | LSa: 18 of 26 (69.2%), SILS: 8 of 26 (30.7%) | LS: 49.3 ± 16.6 (mean ± SD), SILS: 51.4 ± 21.6 (mean ± SD), P = .81 | LS: 26.9 ± 5.5 (mean ± SD), SILS: 27 ± 8.1 (mean ± SD), P = .98 | LS: myeloproliferative disorder in 8 of 26 (30.7%), ITPa in 6 of 26 (23%), hemolytic anemia in 2 of 26 (7.7%), splenic cyst in 1 of 26 (3.8%), splenic infarction in 1 of 26 (3.8%); SILS: myeloproliferative disorder in 3 of 26 (11.5%), ITP in 2 of 26 (7.7%), hemolytic anemia in 2 of 26 (7.7%), splenic cyst in 1 of 26 (3.8%) | GelPOINT | LS: 473.8 ± 331.8 (mean ± SD), SILS: 422.9 ± 443.6 (mean ± SD), P = .77 | 40 | LS: 185.9 ± 76.6 (mean ± SD), SILS: 101.6 ± 31.2 (mean ± SD), P = .003 | LS: 398.1 ± 494.3 (mean ± SD), SILS: 78.9 ± 68.2 (mean ± SD), P = .25 | LS: 5 of 26 (19.2%), SILS: 0 of 26 | LS: 6 of 26 (23%), SILS: 2 of 26 (7.7%) | LS: 5.1 ± 2.5 (mean ± SD), SILS: 4.4 ± 2.8 (mean ± SD), P = .51 | LS: 5 of 26 (19.2%), SILS: 2 of 26 (7.7%) | NRa |
| Choi et al,9 2013, South Korea | Retrospective, comparative study | LS: 18 of 34 (53%), SILS: 16 of 34 (47%) | LS: 45.8 ± 20.2 (mean ± SD), SILS: 51.7 ± 12.7 (mean ± SD), P > .99 | LS: 22.93 ± 2.59 (mean ± SD), SILS: 25.02 ± 4.17 (mean ± SD), P = .422 | LS: ITP in 11 of 34 (32.3%)b; SILS: ITP in 9 of 34 (26.5%)b | OCTO port/glove port | LS: 132.29 ± 72.84 (mean ± SD), SILS: 80.27 ± 38.49 (mean ± SD), P = .109 | 30 | LS: 88.94 ± 21.68 (mean ± SD), SILS: 95.06 ± 32.35 (mean ± SD), P = .603 | LS: 206.25 ± 142.45 (mean ± SD), SILS: 111.11 ± 99.58 (mean ± SD), P = .047 | LS: 0 of 34, SILS: 0 of 34 | LS: 1 of 34 (3%), SILS: 1 of 34 (3%) | LS: 4.67 ± 2.72 (mean ± SD), SILS: 5.13 ± 1.67 (mean ± SD), P = .564 | LS: 2 of 34 (5.9%), SILS: 1 of 34 (3%) | NR |
| Perger et al,26 2013, USA | Prospective, comparative study | LS: 14 of 30 (47%), SILS: 16 of 30 (53%) | LS: 7 (2–17) [median (range)], SILS: 7 (1–15) [median (range)], P = .44 | NR | LS: spherocytosis in 6 of 30 (20%), sickle cell disease in 5 of 30 (17%), ITP in 3 of 30 (10%); SILS: spherocytosis in 8 of 30 (27%), sickle cell disease in 4 of 30 (13%), ITP in 3 of 30 (10%), autoimmune hemolytic anemia in 1 of 30 (3%) | QuadPort | LS: 229 (62–1145) [median (range)], SILS: 169 (49–536) [median (range)], P = .86 | 15 | LS: 99 (51–154) [median (range)], SILS: 84 (40–190) [median (range)], P = .89 | LS: 10 (5–60) [median (range)], SILS: 10 (5–600) [median (range)], P = .61 | LS: 1 of 30 (3%), SILS: 2 of 30 (6%) | NR | LS: 2 (1–5) [median (range)], SILS: 2 (1–8) [median (range)], P = .2 | LS: 2 of 30 (6%), SILS: 3 of 30 (7%) | NR |
| Monclova et al,23 2013, Spain | Prospective, comparative study | LS: 14 of 32 (43.8%), SILS: 8 of 32 (25%), RPASa: 10 of 32 (31.2%) | LS: 55 ± 18 (mean ± SD), SILS: 50 ± 19 (mean ± SD), RPAS: 41 ± 13 (mean ± SD), P = NSa | LS: 28 ± 5 (mean ± SD), SILS: 25 ± 4 (mean ± SD), RPAS: 24 ± 4.5 (mean ± SD), P = NS | LS: ITP in 13 of 14 (93%), autoimmune hemolytic anemia in 1 of 14 (7%); SILS: ITP in 3 of 8 (37.5%), spherocytosis in 2 of 8 (25%), malignancy in 3 of 8 (37.5%); RPAS: ITP in 8 of 10 (80%), autoimmune hemolytic anemia in 1 of 10 (10%), malignancy in 1 of 10 (10%) | 3 ports/multi-access single port | LS: 212 ± 127 (mean ± SD), SILS: 394 ± 153 (mean ± SD), RPAS: 230 ± 87 (mean ± SD), P = .02 | NR | LS: 83 ± 19 (mean ± SD), SILS: 131 ± 43 (mean ± SD), RPAS: 81 ± 22 (mean ± SD), P = .01 | NR | LS: 0 of 14, SILS: 0 of 8, RPAS: 0 of 10 | LS: 1 of 14 (7%), SILS: 1 of 8 (12.5%), RPAS: 0 of 10, P = NS | LS: 5 ± 3 (mean ± SD), SILS: 4 ± 2 (mean ± SD), RPAS: 3 ± 2 (mean ± SD), P = NS | NR | Body Image Indexc—LS: 7.3 ± 2.8, SILS: 5.8 ± 1.3, RPAS: 5.1 ± 0.4, P < .02 |
| Misawa et al,22 2011, Japan | Prospective study | 10 | 53 (24–66) [median (range)] | NR | ITP in 3 of 10 (30%), liver cirrhosis in 2 of 10 (20%), splenic aneurysm in 2 of 10 (20%), splenic simple cyst in 1 of 10 (10%), epithelial cyst in 1 of 10 (10%), splenic tumor in 1 of 10 (10%) | SILS port | 260 (100–580) [median (range)] | 20 | 230 (150–378) [median (range)] | 15 (0–100) [median (range)] | 1 of 10 (10%) | NR | 6.8 ± 2.3 (mean ± SD) | 0 of 10 | NR |
a
ITP = immune thrombocytopenic purpura; LS = laparoscopic splenectomy; NR = not referred; NS = not statistically significant; RPAS = reduced–port access splenectomy; SILS = single–port access splenectomy.
b
The remaining 13 patients had the following diagnoses: autoimmune hemolytic anemia, angiosarcoma, simple cyst, pseudocyst, diffuse large B-cell lymphoma, hemangioma, histiocytic sarcoma, inflammatory pseudotumor, metastatic lung adenocarcinoma, metastatic clear-cell ovarian carcinoma, sclerosing angiomatoid nodular transformation, lymphoid follicular hyperplasia associated with systemic lupus erythematosus, and vascular malformation.
c
The Body Image Index ranges from 4 (lowest) to 20 (highest).